



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hideaki MATSUOKA, et al.

SERIAL NO: 10/540,546

GAU:

FILED: June 24, 2005

EXAMINER:

FOR: METHOD OF SELECTING NOVEL IMMUNOSUPPRESSANT

MAIL STOP PCT

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

## REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

## RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

## CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

## DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon  
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)Surinder Sachar  
Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 274130US0PCT	SERIAL NO. 10/540,546		
 LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hideaki MATSUOKA, et al.			
				FILING DATE June 24, 2005	GROUP		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AG	04/007758	01/22/2004	WO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	X
	AH	00/08048	02/17/2000	WO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	X
	AI	00/10583	03/02/2000	WO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	X
	AJ				<input type="checkbox"/>	<input type="checkbox"/>	
	AK				<input type="checkbox"/>	<input type="checkbox"/>	
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AL	C.A. HASSING et al., A role for histone deacetylase activity in HDAC1-mediated transcriptional repression., Proc. Natl. Acad. Sci. USA, 1998, 95, p. 3519-24					
	AM	A.H. WANG et al., HDAC4, a Human Histone Deacetylase Related to Yeast HDA1, Is a Transcriptional Corepressor., Molecular and Cellular Biology, 1999, p. 7816-27					
	AN	W. FISCHLE et al., Enzymatic Activity Associated with Class II HDACs Is Dependent on a Multiprotein Complex Containing HDAC3 and SMRT/N-CoR., Molecular Cell, Vol. 09 January, 2002 (09.01.02), pages 45 to 57					
	AO	R.A. SHIVDASANI et al., A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development., EMBO J., 1997, 16(3), p.3965-73					
	AP	I. TAKAHASHI et al., Selective Inhibition of IL-2 Gene Expression by Trichostatin A, a Potent Inhibitor of mammalian Histone Deacetylase., The Journal of Antibiotics, 1996, 49 (5), p. 453-7					
	AQ	MATTHEW G. GUENTHER, et al; The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3; MOLECULAR AND CELLULAR BIOLOGY, p. 6091-6101, Vol. 21, No. 18.; 09/2001					
	AR	Joseph J. BUGGY* et al; Cloning and characterization of a novel human histone deacetylase, HDAC8; Biochem. J. 350, 199-205, (2000)					
	AS	Lin Gao, et al; Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family*; THE JOURNAL OF BIOLOGICAL CHEMISTRY; Vol. 277, No. 28., P. 25748-25755; 04/10/2002					
	AT	Ritu Pandey, et al.; Analysis of histone acetyltransferase and histone deacetylase families of <i>Arabidopsis thaliana</i> suggests functional diversification of chromatin modification among multicellular eukaryotes.; Nucleic Acids Research, Vol. 30, No. 23, p. 5036-5055; 2000					
	AU	YUKO FUJIWARA, et al; Arrested Development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1; Proc. Natl. Acad. Sci. USA, Vol. 93, p 12355-12358, October 1996					
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

New U.S. PCT Application No. 10/540,546  
Docket No: 274130US0PCT



STATEMENT OF RELEVANCY

1) References AG, AH and AL-AP have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.

2) References \_\_\_\_\_ have been cited in the corresponding \_\_\_\_\_ Search Report. A copy of these references is being submitted herewith.

3) References AI and AQ-AU are discussed in the specification. A copy of these references is being submitted herewith.

4) References \_\_\_\_\_ are additional prior art known to Applicant. A copy of these references is being submitted herewith.